RGC
Regencell Bioscience Holdings LtdPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Apr 17 Regencell Bioscience Holdings Ltd (RGC) dismissed its independent au…
- R May 8 Regencell Bioscience reported H1 FY2026 results with net loss wideni…
- R May 19 Regencell Bioscience is raising ~$20M in a registered direct offerin…
- R May 22 Regencell Bioscience announced the closing of a ~$20M registered dir…
- R Oct 7 Regencell Bioscience Holdings Ltd filed its annual report on Form 20…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q2 2026: 8 added (0 new), 2 trimmed or exited.
- Short sellersCOVERING
Short interest −18.1% to 656.2K shares. 7.3 days to cover, ≈0.1% of shares.
- TrendUPTREND
1% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 17.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| Legal & General Group Plc | DOUBLED | $779.0K |
| Amundi | DOUBLED | $287.2K |
| UBS Group AG | ADD | $263.1K |
| Vident Advisory, LLC | TRIM | $68.2K |
| MORGAN STANLEY | TRIM | $30.8K |
| Federation des caisses Desjardins du Quebec | ADD | $17.1K |
| CITIGROUP INC | DOUBLED | $11.2K |
| GROUP ONE TRADING LLC | DOUBLED | $5.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| May 27, 2026 | HUI EVANA YEE WAH Director | TO ISSUER | 19,000 sh |
| May 27, 2026 | LO WILLIAM WING YAN DR Director | TO ISSUER | 70,600 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Sep 30, 2026SecBot reports
9 filings · 1 bullish · 5 bearish · 3 neutral- BEARISH 20-FOct 7, 2026
Regencell Bioscience Holdings Ltd filed its annual report on Form 20-F for the fiscal year ended…
The widening net loss and elevated expense run rate suggest the company is burning cash at an accelerated pace despite the recent capital raise. Monitor the DOJ investigation outcome and any updates…
- BEARISH 6-KMay 22, 2026
Regencell Bioscience announced the closing of a ~$20M registered direct offering of 985,222 shares…
The steep discount and pre-revenue, going-concern profile suggest continued downward pressure on RGC shares as the market absorbs the dilutive offering. Monitor for further cash burn updates and any…
- BEARISH 424B5May 19, 2026
Regencell Bioscience is raising ~$20M in a registered direct offering of 985,222 shares at $20.30…
The deep discount and severe dilution signal distress; expect further downside pressure as shares are absorbed. Monitor any subsequent use-of-proceeds updates or signs of operational progress, but…
- BULLISH 6-KMay 19, 2026
Regencell Bioscience Holdings priced a registered direct offering of 985,222 ordinary shares at…
The capital raise extends runway materially for a pre-revenue bioscience company, reducing near-term financing risk. The $19M lead from a new institutional investor signals external validation…
All RGC filing & press-release reports (9)
- 20-F reportOct 7, 2026
- 6-K reportMay 22, 2026
- 424B5 reportMay 19, 2026
- 6-K reportMay 19, 2026
- 6-K reportMay 8, 2026
- 6-K reportApr 17, 2026
- 6-K reportMar 30, 2026
- 6-K reportMar 30, 2026
- 424B5 reportMar 30, 2026